RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Optimisation of inhaled tuberculosis therapies and implications for host–pathogen interactions
Hickey, A., Misra, A., & Robertson, BD. (2011). Optimisation of inhaled tuberculosis therapies and implications for host–pathogen interactions. Tuberculosis, 91(1), 64. https://doi.org/10.1016/j.tube.2010.10.002
Since tuberculosis is primarily a lung disease, inhalation therapies deserve consideration as an important way of conveying anti-tuberculosis drugs and vaccines to the lungs
The use of inhaled drug therapies to relieve the symptoms of respiratory distress can be traced to the use of smoke from the combustion of stramonium alkaloids in the Indus valley several thousands of years ago. In modern times, sophisticated technologies have been developed for treatment of the cause and symptoms of asthma and chronic obstructive pulmonary disease. Several antimicrobials have been delivered to the lungs to treat local infections since the discovery of penicillin, but most of the published reports are off-label studies by clinicians treating intransigent disease. The use of tobramycin to treat Pseudomonas aeruginosa infections in cystic fibrosis may be the most significant antimicrobial product developed for aerosol delivery and is of direct relevance to consideration of inhaled drug therapies for tuberculosis.
